Current Opportunities
Late-Stage Healthcare Companies Seeking Institutional Capital
We currently represent select medical technology companies at the critical inflection point. Each has completed comprehensive due diligence and meets our standards for late-stage development readiness.
Every company has:
· Proven technology with clinical or real-world validation
· Secured intellectual property and freedom to operate
· Strong management team with relevant experience
· Clear regulatory pathway to approval
· Exhausted early-stage funding sources
· Capital requirement of $10-50 million for commercialization
If you're an institutional investor or family office interested in pre-vetted healthcare opportunities at this specific stage, we'd welcome a confidential discussion.
We are currently evaluating several late-stage opportunities in:
· Neurological therapeutics
· Oncology diagnostics and treatment
· Regenerative medicine platforms
· Medical device technologies
· Rehabilitation and mobility solutions
Each opportunity has been rigorously vetted and is positioned for institutional capital deployment.
Contact us to discuss current opportunities that align with your investment criteria.
NEURO20 TECHNOLOGIES
BIOUNBOUND
What We Do
We translate scientific breakthroughs into investment opportunities that institutional capital understands.
Most pharmaceutical and medical device companies struggle at a critical inflection point. The science is proven. Patents are secured. Early funding is exhausted. They need capital for clinical trials, FDA approval, and commercial launch. But they speak research language while institutional investors speak business language.
We bridge that gap.
We work with companies developing treatments for cancer, autoimmune diseases, cardiovascular conditions, neurological disorders, and medical devices that improve patient outcomes. Stage doesn't matter. Technology and values do.